Algert Global LLC Acquires Shares of 2,549 Ascendis Pharma A/S $ASND

Key Points

• Algert Global LLC acquired a new stake in Ascendis Pharma A/S, purchasing 2,549 shares valued at approximately $397,000 in the first quarter.
• Ascendis Pharma A/S experienced a 0.8% increase in stock trading, with current shares priced at $194.30 and a market capitalization of $11.89 billion.
• The company reported $216.28 million in revenue for Q2, surpassing the consensus estimate of $163.17 million, alongside a narrower loss of ($0.93) earnings per share compared to an expected ($1.42).

Algert Global LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,549 shares of the biotechnology company's stock, valued at approximately $397,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $28,000. Quarry LP purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $96,000. Tower Research Capital LLC TRC raised its stake in shares of Ascendis Pharma A/S by 195.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after acquiring an additional 664 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $174,000. Finally, Dearborn Partners LLC purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $203,000.

Ascendis Pharma A/S Trading Up 0.2%

ASND traded up $0.37 during trading hours on Friday, hitting $194.27. 357,323 shares of the company's stock were exchanged, compared to its average volume of 543,273. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $199.99. The firm has a 50 day moving average of $180.19 and a 200 day moving average of $166.19. The firm has a market cap of $11.89 billion, a P/E ratio of -37.65 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. As a group, research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

ASND has been the topic of a number of research analyst reports. Cowen reissued a "buy" rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 19th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat, Ascendis Pharma A/S has an average rating of "Buy" and a consensus price target of $243.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.